Marinus Pharmaceuticals I... (MRNS)
| Bid | 0.55 |
| Market Cap | 30.37M |
| Revenue (ttm) | 30.26M |
| Net Income (ttm) | -149.24M |
| EPS (ttm) | -2.47 |
| PE Ratio (ttm) | -0.22267206477732793 |
| Forward PE | -2.62 |
| Analyst | Hold |
| Ask | 0.55 |
| Volume | 1,100,953 |
| Avg. Volume (20D) | 1,810,773 |
| Open | 0.55 |
| Previous Close | 0.55 |
| Day's Range | 0.55 - 0.55 |
| 52-Week Range | 0.22 - 10.50 |
| Beta | 1.26 |
About MRNS
Marinus Pharmaceuticals, Inc., a pharmaceutical company, focuses on development and commercialization of products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY, an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings. The...
Analyst Forecast
According to 11 analyst ratings, the average rating for MRNS stock is "Hold." The 12-month stock price forecast is $3, which is an increase of 445.45% from the latest price.
Stock ForecastsNext Earnings Release
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago · businesswire.com
Immedica to Acquire Biopharmaceutical Company Marinus Pharmaceuticals, Inc.STOCKHOLM & RADNOR, Pa.--(BUSINESS WIRE)---- $MRNS #MarinusPharma--Immedica Pharma AB (Immedica), a leading global rare disease company, and Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceuti...